On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...